roxifiban acetate

structure in first source

Also Known As:

(2S)-3-(2-((5S)-3-(p-amidinophenyl)-2-isoxazolin-5-yl)acetamido)-2-(carboxyamino)propionic acid, 2-butyl methyl ester, monoacetate; DMP 754; DMP-754; DMP754; methyl N(3)-(2-(3-(4-formamidinophenyl)isoxazolin-5-yl)acetyl)-N(2)-(1-butyloxycarbonyl)-2,3-diaminopropionate

Networked: 2 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Cain, Valerie A: 1 article (01/2003)
2.	Daly, Robert N: 1 article (01/2003)
3.	Ebling, William: 1 article (01/2003)
4.	Gussak, Ihor: 1 article (01/2003)
5.	Kopecky, Stephen L: 1 article (01/2003)
6.	Murphy, Joseph: 1 article (01/2003)
7.	Pieniaszek, Henry J: 1 article (01/2003)
8.	Simonson, Kristen: 1 article (01/2003)
9.	Sy, Sherwin K B: 1 article (01/2003)
10.	Wilcox, Racehl A: 1 article (01/2003)

Related Diseases

1.	Thrombosis (Thrombus) 10/01/1999 - "DMP754 resulted in a significant reduction in thrombus mass and sustained arterial blood flow with 100% prevention of occlusive and nonocclusive thrombosis. " 10/01/1999 - "Additionally, both DMP754 and XV459 (0.1 mg/kg IV or 0.3 to 0.4 mg/kg PO) demonstrated maximal antithrombotic efficacy in preventing electrically induced carotid and coronary artery thrombosis and significant antithrombotic efficacy (P<0.001) at relatively low doses in different settings of arterial thrombosis in the canine model. " 10/01/1999 - "The present study was undertaken to determine intravenous and oral antithrombotic efficacies of DMP754 and XV459 and to compare them with those of other antiplatelet and anticoagulant agents in canine models of arterial thrombosis. "
2.	Stable Angina 01/01/2003 - "This study examined the dose-response effect on inhibition of platelet aggregation by roxifiban (DMP754), a novel oral platelet GP IIb/IIIa receptor inhibitor, and its safety and tolerability in patients with a history of chronic stable angina pectoris. "
3.	Coronary Artery Disease (Coronary Atherosclerosis) 01/01/2003 - "The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease."

Related Drugs and Biologics

1.	Platelet Membrane Glycoprotein IIb
2.	Anticoagulants
3.	roxifiban
4.	XV 459
5.	Platelet Membrane Glycoproteins